CHILD & ADOLESCENT PSYCHOPHARMACOLOGY

FRIDAY-SUNDAY, MARCH 15-17, 2019
Aulani, A Disney Resort & Spa • Ko Olina, Hawai‘i

COURSE DIRECTORS:

Joseph Biederman, MD
Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD
Director, Bressler Program for Autism Spectrum Disorders
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Timothy E. Wilens, MD
Chief, Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School
WELCOME
On behalf of the entire Massachusetts General Hospital Department of Psychiatry, we are proud to welcome you to our conference on Child and Adolescent Psychopharmacology.

Our goal during this conference is to help you provide the best possible care to young patients who suffer from mental health conditions. Our faculty provide a complete update across research developments, assessment tools, barriers to care, and treatment strategies. The agenda is organized into topic-specific modules that include short lectures and Q&A panels. The panels provide the opportunity to ask questions about the content and easily translate evidence into clinical practice.

You have our full attention over the next three days and we will do our very best to help you assess, treat and manage your patients using the latest evidence to inform your decisions.

Enjoy the program!

TARGET AUDIENCE
The target audience for this event is psychiatrists, primary care and family practice physicians, pediatricians, psychologists, nursing professionals, social workers, residents, and other mental health, primary care and pediatric clinicians.

COMPLIMENTARY BREAKFAST, LUNCH AND COFFEE BREAKS
Complimentary breakfast, lunch and coffee breaks will be available to course participants. Please note that dinner will be on your own.

EVALUATION FORMS/CME/CEU CERTIFICATES
Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to the Evaluation and CME Information document in this syllabus for more information. We strongly encourage you to complete the evaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link to claim credit is as follows: www.mghcme.org/child

QUESTIONS
Opportunity for questions will be provided at the end of each module during the panel discussion. Please write your questions on the index cards provided. Cards will be collected during the last 15 minutes of the lecture prior to the start of the panel discussion. Experience has shown that this method is preferable to that of spontaneous questions.

COPYRIGHT
The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department of Psychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotaping are not allowed. Thank you for your cooperation.

CELLULAR TELEPHONES & PAGERS
During the lectures, we ask that you turn your cell phones and pagers to vibrate or off. We also ask that you do not talk on your cell phones inside the meeting room. Thank you for your cooperation.
CONTACT INFORMATION
For questions or comments, please contact MGH Psychiatry Academy member services at 866-644-7792 or mghcme@mgh.harvard.edu.

LEARNING OBJECTIVES
At the end of this educational activity, participants should be able to:

- Recognize the presentation, diagnosis, and current treatment options available for attention deficit and hyperactivity in childhood and adolescence.
- Identify the presentation, diagnosis, and current treatment options available for behavioral problems and pervasive developmental disorders.
- Discuss the presentation, diagnosis, and current treatment options available for depression, psychosis, manic depression, and anxiety.
- Compare and contrast basic neuropharmacology, neuropsychologic testing data, psychopharmacologic properties of compounds, and the implications of psychiatric genetics for guiding day-to-day pediatric psychopharmacology treatment.
- Recognize the risk management issues associated with adolescent substance use disorder and smoking, ethical and safe use of psychotropics, suicide risk and prevention, cardiovascular side effects and medical liability of stimulants, and liability prevention in psychopharmacology.
- Review the comorbidity of ADHD with posttraumatic stress disorder and traumatic brain injury.
- Describe emotional dysregulation, executive function and learning disorders in the context of ADHD.

ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

McLean Hospital designates this live activity for a maximum of 21.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PSYCHOLOGISTS
The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for 21.00 Continuing Education (CE) credits for psychologists.

REGISTERED NURSES
This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 21.00 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

SOCIAL WORKERS
The Collaborative of NASW, Boston College, and Simmons College Schools of Social Work authorizes social work continuing education credits for courses, workshops, and educational programs that meet the criteria outlined in 258 CMR of the Massachusetts Board of Registration of Social Workers.

This program has been approved for 20.50 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 80039-1.
**AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY**  
This program is approved as an ABPN Maintenance of Certification program. It awards up to 21.00 Category 1 CME credits.

**AMERICAN ACADEMY OF FAMILY PHYSICIANS**  
This Live activity, Child and Adolescent Psychopharmacology 2019, with a beginning date of 03/15/2019, has been reviewed and is acceptable for up to 20.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Other CE Licenses:** Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of *AMA PRA Category 1 Credits™* associated with the activity. Providers should check with their regulatory agencies to determine ways in which *AMA PRA Category 1 Credits™* may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.
## AGENDA

**FRIDAY, MARCH 15, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 – 7:45 AM</td>
<td>Registration &amp; Continental Breakfast</td>
</tr>
<tr>
<td>7:45 – 8:00 AM</td>
<td><strong>Introduction</strong>&lt;br&gt;Joseph Biederman, MD, Timothy E. Wilens, MD</td>
</tr>
</tbody>
</table>

**MODULE TOPIC: OVERVIEW OF PEDIATRIC PSYCHOPHARMACOLOGY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 8:20 AM</td>
<td>Diagnosis &amp; Assessment in Pediatric Psychopharmacology&lt;br&gt;Joseph Biederman, MD</td>
</tr>
<tr>
<td>8:20 – 8:40 AM</td>
<td>Implications of Psychiatric Genetics for Psychopharmacology&lt;br&gt;Stephen V. Faraone, PhD</td>
</tr>
<tr>
<td>8:40 – 9:10 AM</td>
<td><strong>Question &amp; Answer Panel</strong>&lt;br&gt;Moderator: Timothy E. Wilens, MD&lt;br&gt;Panelists: Joseph Biederman, MD &amp; Stephen V. Faraone, PhD</td>
</tr>
</tbody>
</table>

**MODULE TOPIC: ADHD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10 – 9:30 AM</td>
<td>ADHD Across the Life Cycle&lt;br&gt;Joseph Biederman, MD</td>
</tr>
<tr>
<td>9:30 – 9:50 AM</td>
<td>Pharmacologic Treatment of ADHD Across the Life Cycle: Stimulants&lt;br&gt;Joseph Biederman, MD</td>
</tr>
<tr>
<td>9:50 – 10:05 AM</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10:05 – 10:25 AM</td>
<td>Pharmacological Treatment of Pediatric ADHD: Nonstimulants&lt;br&gt;Timothy E. Wilens, MD</td>
</tr>
<tr>
<td>10:25 – 10:55 AM</td>
<td><strong>Question &amp; Answer Panel</strong>&lt;br&gt;Moderator: Stephen V. Faraone, PhD&lt;br&gt;Panelists: Joseph Biederman, MD &amp; Timothy E. Wilens, MD</td>
</tr>
</tbody>
</table>

**MODULE TOPIC: SUBSTANCE USE DISORDERS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55 – 11:15 AM</td>
<td>Substance Use Disorders: Part I&lt;br&gt;Timothy E. Wilens, MD</td>
</tr>
<tr>
<td>11:15 – 11:35 AM</td>
<td>Substance Use Disorders: Part II&lt;br&gt;Timothy E. Wilens, MD</td>
</tr>
<tr>
<td>11:35 – 12:05 PM</td>
<td><strong>Question &amp; Answer Discussion</strong>&lt;br&gt;Timothy E. Wilens, MD</td>
</tr>
<tr>
<td>12:05 – 1:00 PM</td>
<td><strong>Lunch</strong></td>
</tr>
</tbody>
</table>
# MODULE TOPIC: MOOD DISORDERS

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 – 1:20 PM</td>
<td>Juvenile Depression</td>
<td>David H. Rubin, MD</td>
</tr>
<tr>
<td>1:20 – 1:40 PM</td>
<td>Juvenile Mania</td>
<td>Janet Wozniak, MD</td>
</tr>
<tr>
<td>1:40 – 1:55 PM</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>1:55 – 2:15 PM</td>
<td>Differentiating Unipolar vs. Bipolar Mood Disorders in the Young</td>
<td>Janet Wozniak, MD</td>
</tr>
</tbody>
</table>
| 2:15 – 2:45 PM | Question & Answer Panel                                               | Moderator: Timothy E. Wilens, MD  
Panelists: Janet Wozniak, MD & David H. Rubin, MD |
| 2:45 – 3:45 PM | Ask the Experts                                                      | Moderator: David H. Rubin, MD  
Joseph Biederman, MD, Timothy E. Wilens, MD, Janet Wozniak, MD |
| 3:45 PM       | Adjourn                                                               |                        |

Adjourn
SATURDAY, MARCH 16, 2019

7:00 – 8:00 AM  Continental Breakfast

MODULE TOPIC: OCD, TOURETTE’S AND ASD

8:00 – 8:20 AM  Obsessive Compulsive Disorder
Barbara J. Coffey, MD, MS

8:20 – 8:40 AM  Tourette’s Disorder & Tics
Barbara J. Coffey, MD, MS

8:40 – 9:00 AM  Are Autistic Traits Clinically Meaningful?
Joseph Biederman, MD

9:00 – 9:45 AM  Question & Answer Panel
Moderator: David H. Rubin, MD
Panelists: Joseph Biederman, MD & Barbara J. Coffey, MD, MS

9:45 – 10:00 AM  Coffee Break

MODULE TOPIC: SCHIZOPHRENIA, PANDAS AND PEDIATRIC MANIA

10:00 – 10:20 AM  Schizophrenia
Janet Wozniak, MD

10:20 – 10:40 AM  PANDAS
Barbara J. Coffey, MD, MS

10:40 – 11:00 AM  Pharmacological Approaches to Pediatric Mania
Janet Wozniak, MD

11:00 – 11:45 AM  Question & Answer Panel
Moderator: Joseph Biederman, MD
Panelists: Janet Wozniak & Barbara J. Coffey, MD, MS

MODULE TOPIC: PSYCHOLOGICAL ASSESSMENT & INTERVENTION

11:45 – 12:05 PM  Cognitive Behavioral Treatment for Young Adults: Education & Psychological Testing
Aude Henin, PhD

12:05 – 1:00 PM  Lunch

1:00 – 1:20 PM  Cognitive Behavioral Therapy for Anxiety in Young Children
Aude Henin, PhD

1:20 – 1:50 PM  Question & Answer Discussion
Aude Henin, PhD

MODULE TOPIC: ANXIETY DISORDERS

1:50 – 2:10 PM  Pediatric Anxiety Disorders
Barbara J. Coffey, MD, MS
2:10 – 2:25 PM  
**Coffee Break**

2:25 – 2:45 PM  
**Using Psychological Assessment to Inform Treatment**  
Aude Henin, PhD

2:45 – 3:25 PM  
**Question & Answer Panel**  
**Moderator:** Joseph Biederman, MD  
**Panelists:** Barbara J. Coffey, MD, MS, Aude Henin, PhD

3:25 – 4:25 PM  
**Ask the Experts**  
**Moderator:** David H. Rubin, MD  
Joseph Biederman, MD, Aude Henin, PhD

4:25 PM  
**Adjourn**
SUNDAY, MARCH 17, 2019

7:00 – 7:45 AM    Registration & Continental Breakfast

7:45 – 8:00 AM    Introduction
Joseph Biederman, MD, Timothy E. Wilens, MD

MODULE TOPIC: DIAGNOSIS AND UNDERPINNINGS OF ADHD

8:00 – 8:20 AM    Definitions and Overview of ADHD
Joseph Biederman, MD

8:20 – 8:40 AM    Genetics of ADHD
Stephen V. Faraone, PhD

8:40 – 9:00 AM    Neuroimaging and ADHD
Stephen V. Faraone, PhD

9:00 – 9:30 AM    Question & Answer Panel
Moderator: Timothy E. Wilens, MD
Panelists: Stephen V. Faraone, PhD, Joseph Biederman, MD

9:30 – 9:45 AM    Coffee Break

MODULE TOPIC: TREATMENT OF ADHD

9:45 – 10:05 AM    Diagnosis of Adult ADHD
Joseph Biederman, MD

10:05 – 10:25 AM    Treatment of ADHD with Stimulants I
Timothy E. Wilens, MD

10:25 – 10:45 AM    Treatment of ADHD with Stimulants II
Timothy E. Wilens, MD

10:45 – 11:05 AM    Pharmacological Treatment of ADHD Across the Life Span: Nonstimulants
Timothy E. Wilens, MD

11:05 – 11:35 AM    Question & Answer Panel
Moderator: Stephen V. Faraone, PhD
Panelists: Joseph Biederman, MD & Timothy E. Wilens, MD

MODULE TOPIC: EMOTIONAL DYSREGULATION, EXECUTIVE FUNCTION AND LEARNING DISORDERS

11:35 – 11:55 AM    Distinguishing Emotional Dysregulation from Mania
Joseph Biederman, MD

11:55 – 12:15 PM    CBT & Psychosocial Treatments in ADHD
Aude Henin, PhD

12:15 – 1:15 PM    Lunch

1:15 – 1:35 PM    ADHD & Education
Aude Henin, PhD
1:35 – 1:55 PM  
**Working and Driving**  
Joseph Biederman, MD

1:55 – 2:25 PM  
**Question & Answer Panel**  
**Moderator:** Timothy E. Wilens, MD  
**Panelists:** Joseph Biederman, MD & Aude Henin, PhD

2:25 – 2:40 PM  
**Coffee Break**

**MODULE TOPIC: ADDRESSING COMORBIDITIES OF ADHD**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:40 – 3:00 PM</td>
<td>ADHD, Tics and Tourette’s Disorder</td>
<td>Barbara J. Coffey, MD, MS</td>
</tr>
<tr>
<td>3:00 – 3:20 PM</td>
<td>Comorbidity of ADHD with Substance Use Disorders and Associated Risk Management Issues</td>
<td>Timothy E. Wilens, MD</td>
</tr>
<tr>
<td>3:20 – 3:40 PM</td>
<td>Management of ADHD in the Context of Autism Spectrum Disorders</td>
<td>Joseph Biederman, MD</td>
</tr>
<tr>
<td>3:40 – 4:00 PM</td>
<td>ADHD, PTSD &amp; TBI</td>
<td>Joseph Biederman, MD</td>
</tr>
<tr>
<td>4:00 – 5:00 PM</td>
<td><strong>Ask the Experts</strong></td>
<td>Moderator: David H. Rubin, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joseph Biederman, MD, Barbara J. Coffey, MD, MS &amp; Timothy E. Wilens, MD</td>
</tr>
<tr>
<td>5:00 PM</td>
<td><strong>Adjourn</strong></td>
<td></td>
</tr>
</tbody>
</table>
FACULTY

PLANNERS & COURSE DIRECTORS

Joseph Biederman, MD (Course Director)
Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD
Director, Bressler Program for Autism Spectrum Disorder
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Timothy E. Wilens, MD (Course Director)
Chief, Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Jane Pimental, MPH
Managing Director
Massachusetts General Hospital Psychiatry Academy

Susan Sprich, PhD (Psychologist Reviewer)
Director, Postgraduate Psychology Education
Director, Cognitive Behavioral Therapy Program
Massachusetts General Hospital
Assistant Professor of Psychology
Harvard Medical School

David H. Rubin, MD (Reviewer)
Director, Child and Adolescent Psychiatry Residency Training
Massachusetts General Hospital and McLean Hospital
Director, Postgraduate Medical Education, Department of Psychiatry
Executive Director, Massachusetts General Hospital Psychiatry Academy
Massachusetts General Hospital

Timothy E. Wilens, MD (Course Director)
Chief, Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

SPEAKERS

Joseph Biederman, MD (Course Director)
Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD
Director, Bressler Program for Autism Spectrum Disorder
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

David H. Rubin, MD (Reviewer)
Director, Child and Adolescent Psychiatry Residency Training
Massachusetts General Hospital and McLean Hospital
Director, Postgraduate Medical Education, Department of Psychiatry
Executive Director, Massachusetts General Hospital Psychiatry Academy
Massachusetts General Hospital

Barbara Coffey, MD, MS
Division Chief, Child and Adolescent Psychiatry
Professor, Department of Psychiatry and Behavioral Sciences
University of Miami Miller School of Medicine

Janet Wozniak, MD
Chair, Quality and Safety, Department of Psychiatry
Director, Child and Adolescent Psychiatry Outpatient Service
Director, Pediatric Bipolar Disorder Clinical and Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School

Stephen V. Faraone, PhD
Distinguished Professor of Psychiatry and of Neuroscience & Physiology
SUNY Upstate Medical University

Aude Henin, PhD
Co-Director, Child Cognitive-Behavioral Therapy Program
Department of Psychiatry
Massachusetts General Hospital
Assistant Professor of Psychology
Harvard Medical School

Timothy E. Wilens, MD (Course Director)
Chief, Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Janet Wozniak, MD
Chair, Quality and Safety, Department of Psychiatry
Director, Child and Adolescent Psychiatry Outpatient Service
Director, Pediatric Bipolar Disorder Clinical and Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
FACULTY DISCLOSURE STATEMENTS

In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:

COMMERCIAL INTEREST
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

FINANCIAL RELATIONSHIPS
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

RELEVANT FINANCIAL RELATIONSHIPS
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

CONFLICT OF INTEREST
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:

<table>
<thead>
<tr>
<th>NAME</th>
<th>COMPANY</th>
<th>RELATIONSHIP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Akili, Jazz Pharma, and Shire</td>
<td>Consultant Fees (Consultant)</td>
</tr>
<tr>
<td></td>
<td>Bracket Global, Ingenix, Prophase, Shire, Sunovion, and Theravance</td>
<td>Royalties paid to Department of Psychiatry at MGH (Licensing copyrights rating scale used for ADHD diagnoses)</td>
</tr>
<tr>
<td></td>
<td>Avekshan LLC</td>
<td>Financial Interest</td>
</tr>
<tr>
<td>Barbara J. Coffey, MD, MS</td>
<td>Partners Healthcare, Nevada Psychiatric Association, Harvard Medical School, Cincinnati Children's Hospital, Bracket, American Academy of Child and Adolescent Psychiatry</td>
<td>Honoraria</td>
</tr>
<tr>
<td></td>
<td>NIMH, Neurocrine Biosciences, Teva/Nuvelution</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>Abide Therapeutics, Teva/Nuvelution</td>
<td>Scientific Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Tourette Association of America; TAA-CDC Partnership</td>
<td>Co-Chair, Medical Advisory Board</td>
</tr>
<tr>
<td>Stephen V. Faraone, PhD</td>
<td>Shire/Takeda, Otsuka, Arbor, Sunovion</td>
<td>Research or CME Funding (PI)</td>
</tr>
<tr>
<td></td>
<td>Akili, Vaya, Vallon, Tris, Ironshore, Supernus, Sunovion, Genomind</td>
<td>Consultant Fees (Consultant)</td>
</tr>
<tr>
<td></td>
<td>NHE Inhibitor Patent, Guildford Press, Oxford University Press</td>
<td>Royalties or IP</td>
</tr>
<tr>
<td></td>
<td>Shire/Takeda, Ironshore, Genomind, Arbor</td>
<td>In-Kind Services</td>
</tr>
<tr>
<td></td>
<td>Akili, Ironshore</td>
<td>Stock/Equity</td>
</tr>
<tr>
<td>Aude Henin, MD</td>
<td>Oxford University Press</td>
<td>Royalties (Book Authorship)</td>
</tr>
<tr>
<td>Susan Sprich, PhD (Psychologist Reviewer)</td>
<td>Oxford University Press</td>
<td>Royalties, for co-authoring treatment manual and client workbook</td>
</tr>
<tr>
<td></td>
<td>Springer</td>
<td>Royalties for editing book</td>
</tr>
<tr>
<td>Timothy E. Wilens, MD</td>
<td>NIH (NIDA)</td>
<td>Grant Support (Research)</td>
</tr>
<tr>
<td></td>
<td>Alcobra, Neurovance/Otsuka, Ironshore, and KemPharm</td>
<td>Consulting Fees</td>
</tr>
<tr>
<td></td>
<td>Guilford Press, Cambridge University Press, Elsevier, Ironshore</td>
<td>Royalties (Published author/ co-editor/co-owner of copyrighted diagnostic questionnaire, licensing agreement)</td>
</tr>
<tr>
<td></td>
<td>US National Football League (ERM Associates), U.S. Minor/Major League Baseball; Phoenix/Gavin House and Bay Cove Human Services</td>
<td>Consulting Fees (Clinical Consultant)</td>
</tr>
<tr>
<td>Janet Wozniak, MD</td>
<td>PCORI</td>
<td>Research Support</td>
</tr>
<tr>
<td></td>
<td>RLS Foundation</td>
<td>Research Support (Spouse)</td>
</tr>
<tr>
<td></td>
<td>Advance Medical, FlexPharma, Merck, Otsuka and Gerson Lehman Group</td>
<td>Consultation Fees (Spouse)</td>
</tr>
<tr>
<td></td>
<td>UptoDate</td>
<td>Royalties (Spouse)</td>
</tr>
</tbody>
</table>

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.
## Child & Adolescent Psychopharmacology

**Friday–Sunday • March 15-17, 2019**

**Aulani, A Disney Resort & Spa • Ko Olina, Hawai’i**

### Curbside Consultants Schedule

<table>
<thead>
<tr>
<th>FACULTY NAME</th>
<th>TOPIC</th>
<th>PROPOSED TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Biederman, MD</td>
<td>Pediatric Psychopharmacology, Autistic Traits, ADHD Across the Life Cycle</td>
<td>Friday, March 15, 11:00 AM – 12:00 PM</td>
</tr>
<tr>
<td>Timothy E. Wilens, MD</td>
<td>Substance Use Disorders</td>
<td>Friday, March 15, 1:00 – 2:00 PM</td>
</tr>
<tr>
<td>Janet Wozniak, MD</td>
<td>Mood Disorders</td>
<td>Saturday, March 16, 9:00 – 10:00 AM</td>
</tr>
<tr>
<td>Joseph Biederman, MD</td>
<td>Psychopharmacology of Autism Spectrum Disorder</td>
<td>Saturday, March 16, 10:00 – 11:00 AM</td>
</tr>
<tr>
<td>Timothy E. Wilens, MD</td>
<td>ADHD Including Comorbidities</td>
<td>Sunday, March 17, 8:00 – 9:00 AM</td>
</tr>
<tr>
<td>Barbara J. Coffey, MD</td>
<td>Pediatric Anxiety Disorders</td>
<td>Sunday, March 17, 2:00 – 3:00 PM</td>
</tr>
</tbody>
</table>
PLEASE NOTE THAT THIS IS NOT THE OFFICIAL PROGRAM EVALUATION

Child & Adolescent Psychopharmacology 2019

Use this page to take notes on the speakers for their presentations. Evaluations will be available for completion online at mghcme.org/child

**Rating scale:** 1 = Strongly Disagree, 2 = Disagree, 3 = Agree, 4 = Strongly Agree.

<table>
<thead>
<tr>
<th>Talk Time and Speaker</th>
<th>Rating</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FRIDAY, MARCH 15, 2019</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:45 AM – 8:00 AM Introduction</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td><strong>MODULE TOPIC: OVERVIEW OF PEDIATRIC PSYCHOPHARMACOLOGY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 – 8:20 AM—Joseph Biederman, MD</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>8:20 – 8:40 AM—Stephen V. Faraone, PhD</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>8:40 – 9:10 AM—Question &amp; Answer Panel</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td><strong>MODULE TOPIC: ADHD</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:10 – 9:30 AM—Joseph Biederman, MD</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>9:30 – 9:50 AM—Joseph Biederman, MD</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>10:05 – 10:25 AM—Timothy E. Wilens, MD</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>10:25 – 10:55 AM—Question &amp; Answer Panel</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td><strong>MODULE TOPIC: SUBSTANCE USE DISORDERS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:55 – 11:15 AM—Timothy E. Wilens, MD</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>11:15 – 11:35 AM—Timothy E. Wilens, MD</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td>11:35 – 12:05 PM—Question &amp; Answer Discussion</td>
<td>1 2 3 4</td>
<td></td>
</tr>
<tr>
<td><strong>MODULE TOPIC: MOOD DISORDERS</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1:00 – 1:20 PM — David H. Rubin, MD

1:20 – 1:40 PM — Janet Wozniak, MD

1:55 – 2:15 PM — Janet Wozniak, MD

2:15 – 2:45 PM — Question & Answer Panel

2:45 – 3:45 PM — Ask the Experts

SATURDAY, MARCH 16, 2019

MODULE TOPIC: OCD, TOURETTE’S AND ASD

8:00 – 8:20 AM — Barbara J. Coffey, MD, MS

8:20 – 8:40 AM — Barbara J. Coffey, MD, MS

8:40 – 9:00 AM — Joseph Biederman, MD

9:00 – 9:45 AM — Question & Answer Panel

MODULE TOPIC: SCHIZOPHRENIA, PANDAS AND PEDIATRIC MANIA

10:00 – 10:20 AM — Janet Wozniak, MD

10:20 – 10:40 AM — Barbara J. Coffey, MD, MS

10:40 – 11:00 AM — Janet R. Wozniak, MD

11:00 – 11:45 AM — Question & Answer Panel

MODULE TOPIC: PSYCHOLOGICAL ASSESSMENT & INTERVENTION

11:45 – 12:05 PM — Aude Henin, PhD

1:00 – 1:20 PM — Aude Henin, PhD

1:20 – 1:50 PM — Question & Answer Discussion

MODULE TOPIC: ANXIETY DISORDERS

1:50 – 2:10 PM — Barbara J. Coffey, MD, MS

2:25 – 2:45 PM — Aude Henin, PhD

2:45 – 3:25 PM — Question & Answer Panel

3:25 – 4:25 PM — Ask the Experts

SUNDAY, MARCH 17, 2019
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 – 8:00 AM</td>
<td>Introduction</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td></td>
<td><strong>MODULE TOPIC: DIAGNOSIS AND UNDERPINNINGS OF ADHD</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 – 8:20 AM</td>
<td>Joseph Biederman, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>8:20 – 8:40 AM</td>
<td>Stephen V. Faraone, PhD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>8:40 – 9:00 AM</td>
<td>Stephen V. Faraone, PhD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>9:00 – 9:30 AM</td>
<td>Question &amp; Answer Panel</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td></td>
<td><strong>MODULE TOPIC: TREATMENT OF ADHD</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45 – 10:05 AM</td>
<td>Joseph Biederman, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>10:05 – 10:25 AM</td>
<td>Timothy E. Wilens, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>10:25 – 10:45 AM</td>
<td>Timothy E. Wilens, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>10:45 – 11:05 AM</td>
<td>Timothy E. Wilens, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>11:05 – 11:35 AM</td>
<td>Question &amp; Answer Panel</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td></td>
<td><strong>MODULE TOPIC: EMOTIONAL DYSREGULATION, EXECUTIVE FUNCTION AND LEARNING DISORDERS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35 – 11:55 PM</td>
<td>Joseph Biederman, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>11:55 – 12:15 PM</td>
<td>Aude Henin, PhD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>1:15 – 1:35 PM</td>
<td>Aude Henin, PhD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>1:35 – 1:55 PM</td>
<td>Joseph Biederman, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>1:55 – 2:25 PM</td>
<td>Question &amp; Answer Panel</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td></td>
<td><strong>MODULE TOPIC: ADDRESSING COMORBIDITIES OF ADHD</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:40 – 3:00 PM</td>
<td>Barbara J. Coffey, MD, MS</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>3:00 – 3:20 PM</td>
<td>Timothy E. Wilens, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>3:20 – 3:40 PM</td>
<td>Joseph Biederman, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>3:40 – 4:00 PM</td>
<td>Joseph Biederman, MD</td>
<td></td>
<td>1 2 3 4</td>
</tr>
<tr>
<td>4:00 – 5:00 PM</td>
<td>Ask the Experts</td>
<td></td>
<td>1 2 3 4</td>
</tr>
</tbody>
</table>

Complete the course evaluation online at

mghcme.org/child
Three Steps to Claiming your CME Credit...

1: Visit www.mghcme.org/child and click on the orange 'Register' button.

2: Enter your 'Academy Login' username and password then click the 'Login' button. If you have forgotten your password, please click the 'Reset Your Password?' button. Once logged in, select your certificate type.

3: Click on the 'Evaluation' button. Once you have completed your evaluation, and attested to the number of sessions you attended, your certificate will be generated. You should claim only the credit commensurate with the extent of your participation in the activity. Complete the evaluation and claim your credit by: April 19, 2019.
How to Reset Your Password...

Please visit [www.mghcme.org/reset](http://www.mghcme.org/reset) and enter the email address that you used to set up your account, and then click Submit.

You will receive an email with instructions to reset your password. The email will also include your username. If you do not receive an email within a few minutes, please check your Spam/Junk Mail folder.

After resetting your password, enter your username and your new password to access and complete the evaluation and claim your credit.

MY USERNAME IS: ________________________________
World Renowned. Locally Accessible.

We are pleased to announce our one-of-a-kind Visiting program that allows our extraordinary Mass General clinicians to work directly with your health care facility.

Mitigate Physician Shortages  
Meet Expanded Patient Demand  
Raise Quality of Care  
Launch New Service Lines  
Provide Clinical Education

How can your organization collaborate with Mass General Psychiatrists or Psychologists?

**Provisional Clinical Services**
- On-site clinical staff for a psychiatry department, hospital or unit
- Length of assignment term customized to your needs
- Our staff can help treat & manage patients, supervise medical students & more

**Interim Leadership**
- Interim clinical or non-clinical leadership for a psychiatry department, hospital or unit
- On-site and remote leadership schedule
- Consult on clinical rotations, didactic curricula and content, grant writing, research collaboration and more may also be combined with this service

**TeleHealth**
- Meet patient care demands for a psychiatry department, hospital or unit
- Our faculty can treat & manage patients and provide doctor to doctor consults
- Dedicated teams from Mass General for short and long-term needs

**Clinical Consultation**
- Focus on improving quality of care for a psychiatry department, hospital or health system
- On-site or telehealth/remote guidance
- Build collaborative care team models in your community to meet patient demand
- Launch new service lines, position for grants, launch QI initiatives & more

**For more Information contact:**
Shauna Futch, (617) 620-3063, sfutch@mgh.harvard.edu